<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615406</url>
  </required_header>
  <id_info>
    <org_study_id>MIP-1404-P105</org_study_id>
    <nct_id>NCT01615406</nct_id>
  </id_info>
  <brief_title>A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer</brief_title>
  <official_title>A Phase 1 Pilot Comparison Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging to Histology in Men With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Insight Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Insight Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label study of up to 24 prostate cancer patients scheduled for
      prostatectomy and/or pelvic lymph node dissection. Patients receive a single IV dose of
      99mTc-MIP-1404 (study drug) followed by SPECT/CT scan 3-6 hours after injection. As standard
      of care, patients will undergo prostatectomy and/or pelvic lymph node dissection (PLND)
      within two weeks of study drug dosing. 99mTc-MIP-1404 image data will be evaluated for
      visible uptake and compared with histopathology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate</measure>
    <time_frame>Within 3-6 hours of dosing SPECT/CT images will be taken</time_frame>
    <description>Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate (as determined by histopathology) in patients undergoing standard of care prostatectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of 99mTc-MIP-1404 will be assessed by measuring Vital Signs (blood pressure and heart rate)Pre-Dose and Post-Dose as well as between 3-6 hours post-dose</measure>
    <time_frame>Vital signs measurements will be taken, an expected average of 30 minutes before and after study drug injection and between 3-6 hours after study drug injection</time_frame>
    <description>Summary tables will present change from pre-dose to post-dose vital signs measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of pelvic lymph node</measure>
    <time_frame>Within 3-6 hours of dosing SPECT/CT images will be taken</time_frame>
    <description>To obtain exploratory tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of pelvic lymph node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of 99mTc-MIP-1404 uptake with respect to PSMA expression</measure>
    <time_frame>PSMA expression analysis will be conducted upon completion of enrollment</time_frame>
    <description>Evaluate the intensity of 99mTc-MIP-1404 uptake with respect to PSMA expression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Drug: 99mTc-MIP-1404</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc MIP 1404</intervention_name>
    <description>A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404</description>
    <arm_group_label>Drug: 99mTc-MIP-1404</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 21 years or older.

          -  Ability to provide signed informed consent and willingness to comply with protocol
             requirements.

          -  Past biopsy indicating the presence of adenocarcinoma of the prostate gland.

          -  Participant is deemed to have tissue suspicious of prostate cancer involvement that is
             amenable to biopsy/resection.

          -  Have had, or will undergo diagnostic CT or MRI imaging prior to surgery.

          -  Participants must agree to use an acceptable form of birth control throughout the
             study period. Participants must use condoms for a period of seven days after study
             drug administration, if engaged in sexual activity.

        Exclusion Criteria:

          -  Participants for whom participating would significantly delay the scheduled standard
             of care therapy.

          -  Participants administered a radioisotope within 5 physical half lives prior to study
             enrollment.

          -  Participants with any medical condition or other circumstances that, in the opinion of
             the investigator, would significantly decrease obtaining reliable data, achieving
             study objectives or completing the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Slawin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanguard Urologic Research Foundation, University of Texas, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996 Sep;2(9):1445-51.</citation>
    <PMID>9816319</PMID>
  </reference>
  <reference>
    <citation>Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43.</citation>
    <PMID>11016653</PMID>
  </reference>
  <reference>
    <citation>Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004 Feb 15;91(3):528-39. Review.</citation>
    <PMID>14755683</PMID>
  </reference>
  <reference>
    <citation>Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006 Apr;30(4):628-36.</citation>
    <PMID>16555021</PMID>
  </reference>
  <reference>
    <citation>Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998 Dec 1;83(11):2259-69. Review.</citation>
    <PMID>9840525</PMID>
  </reference>
  <reference>
    <citation>Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007 Feb 10;25(5):540-7.</citation>
    <PMID>17290063</PMID>
  </reference>
  <reference>
    <citation>Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005 Apr;46(4):634-41.</citation>
    <PMID>15809486</PMID>
  </reference>
  <reference>
    <citation>Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.</citation>
    <PMID>19706750</PMID>
  </reference>
  <reference>
    <citation>Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007 Sep;2(3):182-90. Review.</citation>
    <PMID>18474004</PMID>
  </reference>
  <reference>
    <citation>Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005 May;288(5):C975-81. Review.</citation>
    <PMID>15840561</PMID>
  </reference>
  <reference>
    <citation>Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets. 2005 Jun;9(3):561-70. Review.</citation>
    <PMID>15948673</PMID>
  </reference>
  <reference>
    <citation>Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, Heston WD. Targeted treatment of prostate cancer. J Cell Biochem. 2007 Oct 15;102(3):571-9. Review.</citation>
    <PMID>17685433</PMID>
  </reference>
  <reference>
    <citation>Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism. 1998 Apr;47(4):484-92.</citation>
    <PMID>9550550</PMID>
  </reference>
  <reference>
    <citation>Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003 Sep;85(3):294-310.</citation>
    <PMID>12938720</PMID>
  </reference>
  <reference>
    <citation>Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005 Jun;46(6):1023-7.</citation>
    <PMID>15937315</PMID>
  </reference>
  <reference>
    <citation>Pan ZY, Wolf W. Computer package for the calculation of the radiation dose to patients, based on the MIRD approach. J Nucl Med. 1985 Mar;26(3):318-20.</citation>
    <PMID>3882906</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

